Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus

Lupus erythematosus (LE) is a chronic, multisystem autoimmune disorder which presents with varying phenotypic findings depending on organ involvement. LE subgroups include neonatal lupus erythematosus, drug-induced lupus, systemic lupus erythematosus (SLE), and cutaneous lupus erythematosus (CLE).1,2 CLE may occur in association with or independent of SLE. CLE is further classified into 3 LE-specific cutaneous subtypes based on unique clinical features, histopathology, and immunologic characteristics.